亚型
列线图
肿瘤微环境
原发性中枢神经系统淋巴瘤
危险分层
淋巴瘤
肿瘤科
医学
内科学
多路复用
中枢神经系统
生存分析
CD8型
免疫疗法
弥漫性大B细胞淋巴瘤
生物
癌症研究
总体生存率
计算生物学
免疫学
递归分区
分层(种子)
免疫活性
作者
Xianggui Yuan,Qian Luo,Yurong Huang,Chaoyi Li,Teng Yu,Shanshan Guo,Qunyi Guo,Xueli Jin,Jiefeng Tong,Aiqi Zhao,Wen Lei,Li X,李百周,Shumei Wei,Wenbin Qian,Yun Liang
摘要
ABSTRACT Current prognostic models fail to capture the biological complexity of primary central nervous system lymphoma (PCNSL). We integrated whole‐genome sequencing and multiplex immunofluorescence in 68 treatment‐naïve patients to define four genomic subtypes (C1, C2, C3, and C4) with divergent survival (C4 worst: median overall survival [OS], 26 months). In parallel, a novel tumor microenvironment (TME) classification based on CD8 + T/M2 macrophage ratio stratified patients into High (> 1.5), Intermediate (0.8–1.5), and Low (< 0.8) groups. Unexpectedly, the Intermediate TME group showed the poorest outcomes (5‐year OS: 10%). Integration revealed a lethal subgroup (C4 + Intermediate TME; 9.8% of cohort) with a median OS of 3.0 months (hazard ratio = 7.24, p = 0.006). Prognostic nomograms incorporating these subtypes showed promising discriminative performance in internal validation (C‐index > 0.78), but external validation is needed. Together, these findings identify a high‐risk biological subset and provide a hypothesis‐generating framework for future biomarker‐driven risk stratification and therapeutic discovery in PCNSL.
科研通智能强力驱动
Strongly Powered by AbleSci AI